By Stephen Nakrosis
U.S.-listed shares of Virax Biolabs rose sharply in heavy volume after the British biotechnology company said it reached an agreement with distributor Europa Biosite to commercialize a portfolio of research products in the U.K. and Ireland.
In afternoon trading Wednesday, Virax shares were up 62% at $2.73. Volume in the session topped 80 million shares, above the stock's 65-day average volume of about 4.5 million.
ImmuneSelect is a suite of research products for assessing adaptive immunity.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
October 23, 2024 14:18 ET (18:18 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Comments